CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Mazeron MC

    Mutations:

    Mutant Gene Virus Reference
    N495K UL54 Human betaherpesvirus 5 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Human betaherpesvirus 5 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Human betaherpesvirus 5 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    E2K UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V12L UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    D242G UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A327V UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    E393K UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A425V UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G436E UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    M442T UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A444G UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S445N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    N446del UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    449-451del UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    T452I UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S454N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G460V UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A464T UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V471A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V476A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    E485G UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    R507C UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    Q577R UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    D586N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648R UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648S UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L658F UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S749N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V778A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V793A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    P800L UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    P803A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A812E UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L831M UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G840A UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S848N UL56 Human betaherpesvirus 5 Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    T37A UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L89P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    D94N UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K95E UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    H216R UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    G239C UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    Q244H UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    Q249H UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K253Q UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K253T UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    E254A UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    R258P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A283P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    N294D UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    S345A UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    T448I UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    C511F UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    I531V UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L548V UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    G635S UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A663V UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    D665E UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A668P UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    F671S UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    R672K UL89 Human betaherpesvirus 5 New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230